S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop tumor
cells from dividing so they stop growing or die. Combining more than one drug and giving
drugs in different ways may kill more tumor cells. It is not yet known whether estramustine
plus docetaxel is more effective than mitoxantrone plus prednisone for prostate cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of estramustine plus
docetaxel with that of mitoxantrone plus prednisone in treating patients who have stage IV
prostate cancer that has not responded to hormone therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
Cancer and Leukemia Group B National Cancer Institute (NCI) North Central Cancer Treatment Group